A biomarker is, according to the US National Institutes of Health, 鈥渁 characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.鈥�
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
鈥� Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
鈥� Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
鈥� Proteomic biomarkers: Base on the analysis of the protein profiles.
鈥� Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
Market Analysis and Insights: Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is projected to grow from US$ 22500 million in 2024 to US$ 29810 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
Report Covers:
This report presents an overview of global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Market by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2019-2030)
2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Region
2.2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Region (2019-2024)
2.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2025-2030)
2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Dynamics
2.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
2.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
2.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Players
3.1.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Players (2019-2024)
3.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2019-2024)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio
3.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2023
3.5 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Head office and Area Served
3.6 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Product and Application
3.7 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type
4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2019-2024)
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2025-2030)
5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2019-2024)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
6.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
6.2.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2019-2024)
6.2.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2025-2030)
6.2.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2019-2030)
6.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
6.3.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2019-2024)
6.3.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2025-2030)
6.3.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2019-2030)
6.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
6.4.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
6.4.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
7.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
7.2.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2019-2024)
7.2.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2025-2030)
7.2.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2019-2030)
7.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
7.3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2019-2024)
7.3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2025-2030)
7.3.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2019-2030)
7.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
7.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
7.4.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
8.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
8.2.1 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2019-2024)
8.2.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2025-2030)
8.2.3 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2019-2030)
8.3 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
8.3.1 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2019-2024)
8.3.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2025-2030)
8.3.3 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
9.2 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
9.2.1 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2019-2024)
9.2.2 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2025-2030)
9.2.3 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2019-2030)
9.3 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
9.3.1 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2019-2024)
9.3.2 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2025-2030)
9.3.3 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2019-2030)
9.4 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region
9.4.1 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2019-2024)
9.4.3 Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
10.2.1 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
10.3.1 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
10.4.1 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.1.4 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.1.5 Roche Recent Developments
11.2 Dako (Agilent Technologies)
11.2.1 Dako (Agilent Technologies) Company Details
11.2.2 Dako (Agilent Technologies) Business Overview
11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.2.4 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.2.5 Dako (Agilent Technologies) Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.3.4 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.3.5 Merck Recent Developments
11.4 BD
11.4.1 BD Company Details
11.4.2 BD Business Overview
11.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.4.4 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.4.5 BD Recent Developments
11.5 Abbott
11.5.1 Abbott Company Details
11.5.2 Abbott Business Overview
11.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.5.4 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.5.5 Abbott Recent Developments
11.6 Genesys Biolabs (20/20GeneSystems)
11.6.1 Genesys Biolabs (20/20GeneSystems) Company Details
11.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.6.4 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Developments
11.7 Affymetrix
11.7.1 Affymetrix Company Details
11.7.2 Affymetrix Business Overview
11.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.7.4 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.7.5 Affymetrix Recent Developments
11.8 Agendia
11.8.1 Agendia Company Details
11.8.2 Agendia Business Overview
11.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.8.4 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.8.5 Agendia Recent Developments
11.9 ALMAC
11.9.1 ALMAC Company Details
11.9.2 ALMAC Business Overview
11.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.9.4 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.9.5 ALMAC Recent Developments
11.10 Arrayit
11.10.1 Arrayit Company Details
11.10.2 Arrayit Business Overview
11.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.10.4 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.10.5 Arrayit Recent Developments
11.11 Biocartic
11.11.1 Biocartic Company Details
11.11.2 Biocartic Business Overview
11.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.11.4 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.11.5 Biocartic Recent Developments
11.12 BG Medicine
11.12.1 BG Medicine Company Details
11.12.2 BG Medicine Business Overview
11.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.12.4 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.12.5 BG Medicine Recent Developments
11.13 KEGG EXPRESSION Database
11.13.1 KEGG EXPRESSION Database Company Details
11.13.2 KEGG EXPRESSION Database Business Overview
11.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.13.4 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.13.5 KEGG EXPRESSION Database Recent Developments
11.14 Thermo Fisher
11.14.1 Thermo Fisher Company Details
11.14.2 Thermo Fisher Business Overview
11.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.14.4 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.14.5 Thermo Fisher Recent Developments
11.15 BGI
11.15.1 BGI Company Details
11.15.2 BGI Business Overview
11.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.15.4 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.15.5 BGI Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
听
听
*If Applicable.